Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)

Vertex Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Revenue rose 7.82% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $12.2 billion (up 10.08% YoY), while the FY2025 annual figure was $12.0 billion, up 8.9% from the prior year.
• Revenue was $3.0 billion for Q1 2026 at Vertex Pharmaceuticals, down from $3.2 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $3.2 billion in Q4 2025 to a low of $2.1 billion in Q1 2022.
• Historically, Revenue has averaged $2.6 billion across 5 years, with a median of $2.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue grew 22.46% in 2022, then climbed 2.96% in 2025.
• A 5-year view of Revenue shows it stood at $2.3 billion in 2022, then advanced by 9.34% to $2.5 billion in 2023, then climbed by 15.66% to $2.9 billion in 2024, then climbed by 9.55% to $3.2 billion in 2025, then retreated by 6.37% to $3.0 billion in 2026.
• The last three Revenue figures came in at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.